KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) EBT Margin (2016 - 2025)

Emergent BioSolutions' EBT Margin history spans 15 years, with the latest figure at 34.1% for Q4 2025.

  • For Q4 2025, EBT Margin fell 1992.0% year-over-year to 34.1%; the TTM value through Dec 2025 reached 11.15%, up 2818.0%, while the annual FY2025 figure was 11.15%, 2484.0% up from the prior year.
  • EBT Margin reached 34.1% in Q4 2025 per EBS's latest filing, down from 24.92% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 48.47% in Q3 2024 to a low of 539.6% in Q2 2024.
  • Average EBT Margin over 5 years is 40.44%, with a median of 15.03% recorded in 2021.
  • Peak YoY movement for EBT Margin: plummeted -46555bps in 2024, then surged 52768bps in 2025.
  • A 5-year view of EBT Margin shows it stood at 34.97% in 2021, then plummeted by -153bps to 18.59% in 2022, then dropped by -6bps to 19.7% in 2023, then grew by 28bps to 14.18% in 2024, then plummeted by -141bps to 34.1% in 2025.
  • Per Business Quant, the three most recent readings for EBS's EBT Margin are 34.1% (Q4 2025), 24.92% (Q3 2025), and 11.92% (Q2 2025).